טוען...
Axitinib in metastatic renal cell carcinoma: single center experience
AIM OF THE STUDY: Due to the emergence of new therapeutic opportunities in the second-line treatment of metastatic renal cell carcinoma, the choice of the appropriate medication requires consideration. Making the selection one should take into account the likelihood of response, the probability of t...
שמור ב:
| הוצא לאור ב: | Contemp Oncol (Pozn) |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Termedia Publishing House
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5320462/ https://ncbi.nlm.nih.gov/pubmed/28239287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2016.65609 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|